Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alnylam Pharmaceuticals (ALNY) PT Trimmed to $95 at Chardan Capital Markets
May 5, 2017 10:07 AM EDTChardan Capital Markets lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $95.00 (from $97.00) while maintaining a Buy rating following Q1 results.
Analyst Madhu Kumar commented, "Alnylam's lead asset, patisiran, a RNAi drug targeting transthyretin (TTR), is currently in the phase III APOLLO... More
Alnylam Pharma (ALNY) Tops Q1 EPS by 1c
May 5, 2017 8:01 AM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.25), $0.01 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $19 million versus the consensus estimate of $23.65 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More